Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,420.00
Bid: 12,418.00
Ask: 12,422.00
Change: -8.00 (-0.06%)
Spread: 4.00 (0.032%)
Open: 12,474.00
High: 12,480.00
Low: 12,402.00
Prev. Close: 12,428.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EXECUTIVE CHANGE SUMMARY: Wizz Poaches From easyJet; New Cenkos CEO

Wed, 09th Dec 2020 16:08

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Wednesday and not separately reported by Alliance News:

----------

Wizz Air Holdings PLC - Budapest-based budget airline - Hires Robert Carey as president, starting June 14 next year, to oversee operations and commercial functions. Carey has been chief commercial & strategy officer for rival carrier easyJet PLC since 2017, having started at America West Airlines followed by Delta Airlines and a 10-year stint at McKinsey & Co. Wizz also hires Michael Delehant as executive vice president and chief operations officer, reporting to Carey. Delehant joins from Vueling, the Spanish low-cost airline owned by International Consolidated Airlines Group SA, where he has been chief strategy & network officer. He starts at Wizz on April 1.

----------

Cenkos Securities PLC - London-based stock broker and company advisor - Jim Durkin will retire as chief executive in March of next year, after having returned to Cenkos in 2019. That was a difficult time for UK stockbrokers, Cenkos notes, and Durkin "kept the company profitable, led the restructuring of the board and further strengthened governance". Julian Morse, an executive director and head of the Growth Companies Team, will replace Durkin as CEO. Cenkos says Morse is a founding member of the Growth Companies Team and has led it since 2016. Cenkos also promotes Jeremy Osler, co-head of Corporate Finance & general counsel, to the board as an executive director. Osler joined Cenkos in 2016.

----------

London Stock Exchange Group PLC - trading and clearing operator and index calculator - Proposes Martin Brand, Erin Brown and Douglas Steenland as board directors. The appointments are part of LSEG's acquisition of market data and trading platform provider Refinitiv, following which the shareholders of Refinitiv will have the right to nominate three non-executive directors for as long as they continue to hold at least 25% of LSEG. Brand and Steenland will represent Blackstone, and Brown will represent Thomson Reuters. Brand is a senior managing director and co-head of US Acquisitions for Blackstone's Private Equity Group. Steenland is a a senior adviser to the Blackstone Private Equity Group. Brown is head of Finance for the Thomson Reuters Corporates segment. LSEG expects the Refinitiv acquisition to complete in the first quarter of next year.

----------

Aviva PLC - London-based life and general insurer - Hires Pippa Lambert as independent non-executive director, starting January 1. Lambert was global head of Human Resources at Deutsche Bank AG and before that head of Reward at Royal Bank of Scotland.

----------

OptiBiotix Health PLC - York, England-based developer of compounds to treat obesity, high cholesterol, diabetes and skincare - Hires Christopher Brinsmead as director. Brinsmead was president of AstraZeneca UK & Ireland, part of AstraZeneca PLC, until 2010 and before that president of the Association of the British Pharamaceutical Industry.

----------

Network International Holdings PLC - Middle East-focused payment solutions provider - Hires Diane Radley and Monique Shivanandan as independent non-executive directors, starting January 1. Radley led the Transaction Services Group at PwC South Africa. She also was CEO of Old Mutual Investment Group from 2011 to 2016, having been finance director prior to that. Shivanandan is chief information officer at property and casualty insurance firm Chubb Ltd and also a non-executive director for JP Morgan Securities in the UK.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
13 Dec 2023 17:07

UK's FTSE 100 rises as pound slips on GDP data; awaits Fed rate decision

UK economy shrinks by 0.3% in October

*

Read more
12 Dec 2023 16:00

London close: Stocks slip as investors digest US inflation

(Sharecast News) - London's markets finished in the red on Tuesday, as investors digested a slight decrease in consumer inflation in the US, while the UK's unemployment figures remained stable.

Read more
12 Dec 2023 12:07

London midday: FTSE still firmer ahead of US inflation print

(Sharecast News) - London's markets remained relatively stable by midday on Tuesday, with the top-flight index still in the green after fresh jobs data showed a slowdown in wage growth.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:53

LONDON MARKET OPEN: FTSE 100 opens higher ahead of US CPI

(Alliance News) - Stock prices in London opened higher on Tuesday, as investors digest the latest UK unemployment data, before turning their eyes to US inflation this afternoon.

Read more
12 Dec 2023 08:37

AstraZeneca acquires vaccine developer Icosavax for USD1.1 billion

(Alliance News) - AstraZeneca PLC confirmed on Tuesday that it will buy Icosavax Inc, boosting its vaccine portfolio with an "innovative" treatment for respiratory viruses.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:16

AstraZeneca to buy US vaccine maker Icosavax for up to $1.1bn

(Sharecast News) - AstraZeneca said on Tuesday that it has agreed to buy Icosavax - a US-based clinical-stage biopharmaceutical company - for up to $1.1bn.

Read more
12 Dec 2023 02:00

UK companies pause China investment decisions as economy slows, survey shows

BEIJING, Dec 12 (Reuters) - A slowdown in both the Chinese and global economies is the biggest issue affecting British firms in the world's second-largest economy, beating geopolitical concerns and market access barriers, according to the British Chamber of Commerce in China.

Read more
11 Dec 2023 08:15

AstraZeneca says danicopan tests well as blood disorder treatment

(Alliance News) - AstraZeneca PLC on Monday reported "positive results" from a test of danicopan for the treatment of paroxysmal nocturnal haemoglobinuria, or PNH, a rare and severe blood disorder.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
1 Dec 2023 08:52

LONDON MARKET OPEN: Miners give FTSE 100 boost thanks to China PMI

(Alliance News) - Stock prices in London opened higher on Friday, with the FTSE 100 boosted by mining stocks.

Read more
1 Dec 2023 08:33

AstraZeneca discontinues two phase III evidence trials for Lokelma

(Alliance News) - AstraZeneca on Friday said it has decided to discontinue the Stabilize-CKD and Dialize-outcomes phase III trials for Lokelma, citing increased enrolment timelines.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.